معرفی
Mikael Elofsson is a Professor and Dean of the Faculty of Science and Technology at Umeå University. He holds a PhD from the Lund Institute of Technology (1996) and completed postdoctoral research at Yale University. His research focuses on antiviral and antibacterial compounds, particularly targeting viral entry mechanisms and bacterial virulence systems. Key projects include developing glycoconjugates and small molecules against adenoviruses, coxsackieviruses, and Pseudomonas aeruginosa. He leads the Mikael Elofsson lab, exploring chemical probes for ADP-ribosyltransferases and epigenetic signaling. Notable collaborations include work with AstraZeneca on antiviral drug discovery.
- Education: PhD in Organic Chemistry (1996, Lund Institute of Technology); Postdoc at Yale University (1996–1999)
- Affiliations: Department of Chemistry, Faculty of Science and Technology, Umeå University
Research interests span antiviral drug development, bacterial virulence inhibition, and epigenetic modifiers. His lab’s work on salicylidene acylhydrazides led to the FDA-approved drug Kyprolis (Carfilzomib). Current projects include inhibitors for type III secretion systems and ADP-ribosyltransferases, with applications in infectious diseases and cancer.
Publications highlight advancements in antiviral small molecules (e.g., benzavir-2), trivalent sialic acid inhibitors for adenoviruses, and structure-based design of PARP inhibitors. His work bridges chemistry and biology, with a focus on translational medicine.
